Eventide Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.2M | Buy |
1,414,081
+236,019
| +20% | +$2.21M | 0.23% | 116 |
|
|
2025
Q1 | $14.5M | Hold |
1,178,062
| – | – | 0.29% | 102 |
|
|
2024
Q4 | $15.6M | Buy |
1,178,062
+391,072
| +50% | +$5.17M | 0.28% | 110 |
|
|
2024
Q3 | $15.1M | Buy |
+786,990
| New | +$15.1M | 0.26% | 102 |
|
|
2022
Q2 | – | Sell |
-1,165,000
| Closed | -$20.2M | – | 145 |
|
|
2022
Q1 | $20.2M | Hold |
1,165,000
| – | – | 0.32% | 87 |
|
|
2021
Q4 | $25.5M | Hold |
1,165,000
| – | – | 0.33% | 83 |
|
|
2021
Q3 | $22.3M | Buy |
1,165,000
+462,652
| +66% | +$8.84M | 0.29% | 89 |
|
|
2021
Q2 | $12.1M | Sell |
702,348
-1,314,645
| -65% | -$22.6M | 0.16% | 113 |
|
|
2021
Q1 | $45.1M | Buy |
2,016,993
+70,993
| +4% | +$1.59M | 0.67% | 56 |
|
|
2020
Q4 | $43.3M | Buy |
1,946,000
+1,246,800
| +178% | +$27.7M | 0.66% | 54 |
|
|
2020
Q3 | $10.3M | Buy |
699,200
+206,700
| +42% | +$3.05M | 0.2% | 101 |
|
|
2020
Q2 | $7.3M | Buy |
492,500
+265,820
| +117% | +$3.94M | 0.16% | 98 |
|
|
2020
Q1 | $2.49M | Buy |
+226,680
| New | +$2.49M | 0.08% | 103 |
|
|
2017
Q4 | – | Sell |
-225,000
| Closed | -$2.63M | – | 144 |
|
|
2017
Q3 | $2.63M | Hold |
225,000
| – | – | 0.15% | 96 |
|
|
2017
Q2 | $3.14M | Buy |
+225,000
| New | +$3.14M | 0.2% | 87 |
|